278 related articles for article (PubMed ID: 8465478)
1. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
Kleinknecht S; Bichler KH; Strohmaier WL
Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
[TBL] [Abstract][Full Text] [Related]
2. [Study of adoptive immunotherapy with lymphokine-activated killer (LAK) cells and interleukin-2 for metastatic renal cell carcinoma. I. Generation of LAK cells by incubation in serum-free medium].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):822-30. PubMed ID: 8320887
[TBL] [Abstract][Full Text] [Related]
3. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
4. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
5. Different lymphoid cell populations produce varied levels of neopterin, beta 2-microglobulin and soluble IL-2 receptor when stimulated with IL-2, interferon-gamma or tumour necrosis factor-alpha.
Hofmann B; Bass H; Nishanian P; Faisal M; Figlin RA; Sarna GP; Fahey JL
Clin Exp Immunol; 1992 Jun; 88(3):548-54. PubMed ID: 1606739
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
7. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
8. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
9. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
[TBL] [Abstract][Full Text] [Related]
11. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
12. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
13. Association between biosynthesis of nitric oxide and changes in immunological and vascular parameters in patients treated with interleukin-2.
Miles D; Thomsen L; Balkwill F; Thavasu P; Moncada S
Eur J Clin Invest; 1994 Apr; 24(4):287-90. PubMed ID: 8050458
[TBL] [Abstract][Full Text] [Related]
14. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
Nomura K; Fujioka T
Nihon Hinyokika Gakkai Zasshi; 1993 May; 84(5):831-40. PubMed ID: 8320888
[TBL] [Abstract][Full Text] [Related]
15. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
17. Immune status and immune therapy of renal cell carcinoma.
Bichler KH; Kleinknecht S; Strohmaier WL
Urol Int; 1990; 45(5):269-83. PubMed ID: 2219564
[TBL] [Abstract][Full Text] [Related]
18. [Study on adoptive immunotherapy on patients with renal cell carcinoma. I. Functional characteristics of peripheral blood mononuclear cells and serum immunosuppressive factors in patients with renal cell carcinoma].
Usui A
Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1051-7. PubMed ID: 2214468
[TBL] [Abstract][Full Text] [Related]
19. In vivo activation of LAK cells during systemic IL-2 therapy.
Lang P; Vitté-Mony I; Farace F; Stancou R; Triebel F; Escudier B; Hercend T; Bertoglio J
Eur Cytokine Netw; 1990; 1(3):185-8. PubMed ID: 2129800
[No Abstract] [Full Text] [Related]
20. Secondary cytokine production by lymphoid cells used in cellular immunotherapy.
Schoof DD; Hunt P; Obando JA; Cusack JC; Andrews V; Terashima Y; Eberlein TJ
Surg Oncol; 1992 Apr; 1(2):163-72. PubMed ID: 1341247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
